Related references
Note: Only part of the references are listed.Candida guilliermondii and Other Species of Candida Misidentified as Candida famata: Assessment by Vitek 2, DNA Sequencing Analysis, and Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry in Two Global Antifungal Surveillance Programs
Mariana Castanheira et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2013)
Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Amphotericin B and Flucytosine
A. Espinel-Ingroff et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations
Maiken Cavling Arendrup et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Changes in Incidence and Antifungal Drug Resistance in Candidemia: Results From Population-Based Laboratory Surveillance in Atlanta and Baltimore, 2008-2011
Angela Ahlquist Cleveland et al.
CLINICAL INFECTIOUS DISEASES (2012)
The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012
Nkechi Azie et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2012)
Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008
Michael Pfaller et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2012)
Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes
Shellee A. Grim et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey
Javier Peman et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2012)
Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2012)
Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Programme
Michael A. Pfaller et al.
MYCOPATHOLOGIA (2012)
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria
Michael A. Pfaller et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009)
Michael A. Pfaller et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria
M. A. Pfaller et al.
DRUG RESISTANCE UPDATES (2011)
Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies
Alexandre Alanio et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)
Michael A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2011)
Current issues in the clinical management of invasive candida infections - the AGIHO, DMykG, OGMM and PEG web-based survey and expert consensus conference 2009
M. Karthaus et al.
MYCOSES (2011)
Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection
Susan Julie Howard et al.
MEDICAL MYCOLOGY (2011)
Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007-2009
Jan W. M. van der Linden et al.
EMERGING INFECTIOUS DISEASES (2011)
Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Epidemiology of invasive candidiasis
Maiken C. Arendrup
CURRENT OPINION IN CRITICAL CARE (2010)
Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida Time for harmonization of CLSI and EUCAST broth microdilution methods
M. A. Pfaller et al.
DRUG RESISTANCE UPDATES (2010)
Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009
Ahmed Bueid et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp.
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
Breakthrough Invasive Candidiasis in Patients on Micafungin
Christopher D. Pfeiffer et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Triazoles and Six Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)
A. Espinel-Ingroff et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2010)
In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?
Susanne Perkhofer et al.
Current Infectious Disease Reports (2010)
Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target Species
Maiken Cavling Arendrup et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2009)
Sequence-Based Identification of Aspergillus, Fusarium, and Mucorales Species in the Clinical Mycology Laboratory: Where Are We and Where Should We Go from Here?
S. A. Balajee et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
Patterns of Susceptibility of Aspergillus Isolates Recovered from Patients Enrolled in the Transplant-Associated Infection Surveillance Network
John W. Baddley et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure
Susan J. Howard et al.
EMERGING INFECTIOUS DISEASES (2009)
Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus
Juan Luis Rodriguez-Tudela et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
EUCAST Definitive Document EDef 7.1:: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts
J. L. Rodriguez-Tudela et al.
CLINICAL MICROBIOLOGY AND INFECTION (2008)
Infections caused by Scedosporium spp.
Karoll J. Cortez et al.
CLINICAL MICROBIOLOGY REVIEWS (2008)
Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods
Ana Alastruey-Izquierdo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.:: Results from a global Antifungal Surveillance Program
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2008)
Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections
Michael D. Parkins et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Does one voriconazole breakpoint suit all Candida species?
Maiken Cavling Arendrup et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Molecular identification of unusual pathogenic yeast isolates by large ribosomal subunit gene sequencing: 2 years of experience at the United Kingdom Mycology Reference Laboratory
Christopher J. Linton et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Contemporary tools for the diagnosis and management of invasive mycoses
Barbara D. Alexander et al.
CLINICAL INFECTIOUS DISEASES (2006)
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions
II Raad et al.
CLINICAL INFECTIOUS DISEASES (2006)
Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases
JAH van Burik et al.
CLINICAL INFECTIOUS DISEASES (2006)
Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions
SN Leaw et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
Triazole cross-resistance among candida spp.: Case report, occurrence among bloodstream isolates, and implications for antifungal therapy
SS Magill et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
Initial results from a longitudinal international surveillance programme for anidulafungin (2003)
SA Messer et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia
JW Baddley et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2004)
Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi
DJ Diekema et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2003)
Voriconazole treatment for less-common, emerging, or refractory fungal infections
JR Perfect et al.
CLINICAL INFECTIOUS DISEASES (2003)
Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients
S Hadley et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2002)
Antifungal susceptibility testing: Practical aspects and current challenges
JH Rex et al.
CLINICAL MICROBIOLOGY REVIEWS (2001)
Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: Case report and literature review of central nervous system pseudallescheriasis
MA Nesky et al.
CLINICAL INFECTIOUS DISEASES (2000)